These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

433 related articles for article (PubMed ID: 29298117)

  • 1. Association of Cell-Free DNA Tumor Fraction and Somatic Copy Number Alterations With Survival in Metastatic Triple-Negative Breast Cancer.
    Stover DG; Parsons HA; Ha G; Freeman SS; Barry WT; Guo H; Choudhury AD; Gydush G; Reed SC; Rhoades J; Rotem D; Hughes ME; Dillon DA; Partridge AH; Wagle N; Krop IE; Getz G; Golub TR; Love JC; Winer EP; Tolaney SM; Lin NU; Adalsteinsson VA
    J Clin Oncol; 2018 Feb; 36(6):543-553. PubMed ID: 29298117
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exploring the prognostic significance of arm-level copy number alterations in triple-negative breast cancer.
    Doré S; Ali M; Sorin M; McDowell SAC; Desharnais L; Breton V; Yu MW; Arabzadeh A; Ryan MI; Milette S; Quail DF; Walsh LA
    Oncogene; 2024 Jun; 43(26):2015-2024. PubMed ID: 38744952
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor fraction-guided cell-free DNA profiling in metastatic solid tumor patients.
    Tsui DWY; Cheng ML; Shady M; Yang JL; Stephens D; Won H; Srinivasan P; Huberman K; Meng F; Jing X; Patel J; Hasan M; Johnson I; Gedvilaite E; Houck-Loomis B; Socci ND; Selcuklu SD; Seshan VE; Zhang H; Chakravarty D; Zehir A; Benayed R; Arcila M; Ladanyi M; Funt SA; Feldman DR; Li BT; Razavi P; Rosenberg J; Bajorin D; Iyer G; Abida W; Scher HI; Rathkopf D; Viale A; Berger MF; Solit DB
    Genome Med; 2021 May; 13(1):96. PubMed ID: 34059130
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Integrated molecular profiling of young and elderly patients with triple-negative breast cancer indicates different biological bases and clinical management strategies.
    Ma D; Jiang YZ; Xiao Y; Xie MD; Zhao S; Jin X; Xu XE; Shao ZM
    Cancer; 2020 Jul; 126(14):3209-3218. PubMed ID: 32383785
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Integration of whole-genome sequencing and functional screening identifies a prognostic signature for lung metastasis in triple-negative breast cancer.
    Xie G; Yang H; Ma D; Sun Y; Chen H; Hu X; Jiang YZ; Shao ZM
    Int J Cancer; 2019 Nov; 145(10):2850-2860. PubMed ID: 30977117
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CCNE1 amplification is associated with poor prognosis in patients with triple negative breast cancer.
    Zhao ZM; Yost SE; Hutchinson KE; Li SM; Yuan YC; Noorbakhsh J; Liu Z; Warden C; Johnson RM; Wu X; Chuang JH; Yuan Y
    BMC Cancer; 2019 Jan; 19(1):96. PubMed ID: 30665374
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low-pass Whole-genome Sequencing of Circulating Cell-free DNA Demonstrates Dynamic Changes in Genomic Copy Number in a Squamous Lung Cancer Clinical Cohort.
    Chen X; Chang CW; Spoerke JM; Yoh KE; Kapoor V; Baudo C; Aimi J; Yu M; Liang-Chu MMY; Suttmann R; Huw LY; Gendreau S; Cummings C; Lackner MR
    Clin Cancer Res; 2019 Apr; 25(7):2254-2263. PubMed ID: 30617129
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Copy number alterations analysis of primary tumor tissue and circulating tumor cells from patients with early-stage triple negative breast cancer.
    Silvestri M; Dugo M; Vismara M; De Cecco L; Lanzoni D; Vingiani A; Folli S; De Santis MC; de Braud F; Pruneri G; Di Cosimo S; Cappelletti V
    Sci Rep; 2022 Jan; 12(1):1470. PubMed ID: 35087134
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HAGE in Triple-Negative Breast Cancer Is a Novel Prognostic, Predictive, and Actionable Biomarker: A Transcriptomic and Protein Expression Analysis.
    Abdel-Fatah TM; McArdle SE; Agarwal D; Moseley PM; Green AR; Ball GR; Pockley AG; Ellis IO; Rees RC; Chan SY
    Clin Cancer Res; 2016 Feb; 22(4):905-14. PubMed ID: 26240276
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic characterization of Polish ccRCC patients: somatic mutation analysis of PBRM1, BAP1 and KDMC5, genomic SNP array analysis in tumor biopsy and preliminary results of chromosome aberrations analysis in plasma cell free DNA.
    Kluzek K; Srebniak MI; Majer W; Ida A; Milecki T; Huminska K; van der Helm RM; Silesian A; Wrzesinski TM; Wojciechowicz J; Beverloo BH; Kwias Z; Bluyssen HAR; Wesoly J
    Oncotarget; 2017 Apr; 8(17):28558-28574. PubMed ID: 28212566
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Profiling molecular regulators of recurrence in chemorefractory triple-negative breast cancers.
    Hancock BA; Chen YH; Solzak JP; Ahmad MN; Wedge DC; Brinza D; Scafe C; Veitch J; Gottimukkala R; Short W; Atale RV; Ivan M; Badve SS; Schneider BP; Lu X; Miller KD; Radovich M
    Breast Cancer Res; 2019 Aug; 21(1):87. PubMed ID: 31383035
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Circulating tumor DNA alterations in patients with metastatic castration-resistant prostate cancer.
    Sonpavde G; Agarwal N; Pond GR; Nagy RJ; Nussenzveig RH; Hahn AW; Sartor O; Gourdin TS; Nandagopal L; Ledet EM; Naik G; Armstrong AJ; Wang J; Bilen MA; Gupta S; Grivas P; Pal SK; Lanman RB; Talasaz A; Lilly MB
    Cancer; 2019 May; 125(9):1459-1469. PubMed ID: 30620391
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genome-wide profiling of circulating tumor DNA depicts landscape of copy number alterations in pancreatic cancer with liver metastasis.
    Wei T; Zhang J; Li J; Chen Q; Zhi X; Tao W; Ma J; Yang J; Lou Y; Ma T; Li X; Zhang Q; Chen W; Que R; Gao S; Bai X; Liang T
    Mol Oncol; 2020 Sep; 14(9):1966-1977. PubMed ID: 32593194
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Breast and prostate cancers harbor common somatic copy number alterations that consistently differ by race and are associated with survival.
    Chen Y; Sadasivan SM; She R; Datta I; Taneja K; Chitale D; Gupta N; Davis MB; Newman LA; Rogers CG; Paris PL; Li J; Rybicki BA; Levin AM
    BMC Med Genomics; 2020 Aug; 13(1):116. PubMed ID: 32819446
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Copy number alteration is an independent prognostic biomarker in triple-negative breast cancer patients.
    Nagahashi M; Ling Y; Toshikawa C; Hayashida T; Kitagawa Y; Futamura M; Kuwayama T; Nakamura S; Yamauchi H; Yamauchi T; Kaneko K; Kanbayashi C; Sato N; Tsuchida J; Moro K; Nakajima M; Shimada Y; Ichikawa H; Lyle S; Miyoshi Y; Takabe K; Okuda S; Wakai T
    Breast Cancer; 2023 Jul; 30(4):584-595. PubMed ID: 36930419
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic role of PIK3CA mutations of cell-free DNA in early-stage triple negative breast cancer.
    Takeshita T; Yamamoto Y; Yamamoto-Ibusuki M; Inao T; Sueta A; Fujiwara S; Omoto Y; Iwase H
    Cancer Sci; 2015 Nov; 106(11):1582-9. PubMed ID: 26353837
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Copy number aberrations in circulating tumor DNA enables prognosis prediction and molecular characterization of breast cancer.
    Kim MH; Kim GM; Ahn JM; Ryu WJ; Kim SG; Kim JH; Kim TY; Han HJ; Kim JY; Park HS; Park S; Park BW; Kim SI; Jeong J; Lee J; Paik S; Kim S; Jung KH; Cho EH; Sohn J
    J Natl Cancer Inst; 2023 Sep; 115(9):1036-1049. PubMed ID: 37166557
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Whole genome deep sequencing analysis of cell-free DNA in samples with low tumour content.
    Ganesamoorthy D; Robertson AJ; Chen W; Hall MB; Cao MD; Ferguson K; Lakhani SR; Nones K; Simpson PT; Coin LJM
    BMC Cancer; 2022 Jan; 22(1):85. PubMed ID: 35057759
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genomic features of rapid versus late relapse in triple negative breast cancer.
    Zhang Y; Asad S; Weber Z; Tallman D; Nock W; Wyse M; Bey JF; Dean KL; Adams EJ; Stockard S; Singh J; Winer EP; Lin NU; Jiang YZ; Ma D; Wang P; Shi L; Huang W; Shao ZM; Cherian M; Lustberg MB; Ramaswamy B; Sardesai S; VanDeusen J; Williams N; Wesolowski R; Obeng-Gyasi S; Sizemore GM; Sizemore ST; Verschraegen C; Stover DG
    BMC Cancer; 2021 May; 21(1):568. PubMed ID: 34006255
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discordant and heterogeneous clinically relevant genomic alterations in circulating tumor cells vs plasma DNA from men with metastatic castration resistant prostate cancer.
    Gupta S; Hovelson DH; Kemeny G; Halabi S; Foo WC; Anand M; Somarelli JA; Tomlins SA; Antonarakis ES; Luo J; Dittamore RV; George DJ; Rothwell C; Nanus DM; Armstrong AJ; Gregory SG
    Genes Chromosomes Cancer; 2020 Apr; 59(4):225-239. PubMed ID: 31705765
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.